Palmar plantar erythrodysesthesia risk factors: Difference between revisions
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Palmar plantar erythrodysesthesia}} | {{Palmar plantar erythrodysesthesia}} | ||
==Overview== | ==Overview== | ||
| Line 44: | Line 42: | ||
*Sorafenib<ref name="pmid215373732" /> | *Sorafenib<ref name="pmid215373732" /> | ||
*Vinorelbine<ref name="pmid215373732" /> | *Vinorelbine<ref name="pmid215373732" /> | ||
==References== | ==References== | ||
Revision as of 13:49, 7 October 2018
|
Palmar plantar erythrodysesthesia Microchapters |
|
Differentiating Palmar plantar erythrodysesthesia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Palmar plantar erythrodysesthesia risk factors On the Web |
|
American Roentgen Ray Society Images of Palmar plantar erythrodysesthesia risk factors |
|
Directions to Hospitals Treating Palmar plantar erythrodysesthesia |
|
Risk calculators and risk factors for Palmar plantar erythrodysesthesia risk factors |
Overview
The most common and established risk factors are chemotherapeutic agents. The severity of the condition depends on the dose and frequency of the agent. The data is limited to support any other associated risk factors as the pathophysiology of Palmar plantar erythrodysesthesia is still unknown even though different mechanisms have been postulated.
Risk Factors
Palmar Plantar Erythrosysesthesia has been linked with The occurrence of this condition has been linked to dose and prolonged chemotherapeutic drug exposure especially with more continuous IV infusion, daily ingestion and liposomal encapsulationg of PLD which prolong half-life of drug. The use of cooling mechanism, higher number of PLD cycles, and occurrence of mucositis, neutropenia and peripheral neuropathy are possible predictors of PPE.[1]
Risk Factors
Exposure to chemotherapeutic agents has been proven to be an established risk factor. Occurrence of this condition has been linked to dose and prolonged chemotherapeutic drug exposure especially with more continuous IV infusion, daily ingestion and liposomal encapsulationg of PLD which prolong half-life of drug. The use of cooling mechanism, higher number of PLD cycles, and occurrence of mucositis, neutropenia and peripheral neuropathy are possible predictors of PPE. [2]
Several agents may be linked with the condition but the Most frequently associated are[3]:
- Doxorubicin (Pegylated liposomal Doxorubicin)
- 5-Flurouracil
- Cytarabine.
Common Causes
- Several different Chemotherapeutic agents have been associated with acral erythema[4]. Common ones are listed below.
Less Common Causes
Causes in Alphabetical Order
- 5-Flurouracil[3]
- Capecitabine[7]
- Capacitabine-based chemotherapy[8]
- Cytarabine[3]
- Docetaxel[7]
- Doxorubicin (Pegylated liposomal Doxorubicin)[3]
- Gemcitabine[7]
- Methotrexate - even low dose used to treat ALL[5]
- Mitotane[6]
- PLD[7]
- Sorafenib[7]
- Vinorelbine[7]
References
- ↑ Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK (2009). "Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer". Gynecol Oncol. 114 (2): 219–24. doi:10.1016/j.ygyno.2009.04.007. PMID 19446868.
- ↑ Tanyi JL, Smith JA, Ramos L, Parker CL, Munsell MF, Wolf JK (2009). "Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer". Gynecol Oncol. 114 (2): 219–24. doi:10.1016/j.ygyno.2009.04.007. PMID 19446868.
- ↑ 3.0 3.1 3.2 3.3 3.4 Webster-Gandy JD, How C, Harrold K (2007). "Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre". Eur J Oncol Nurs. 11 (3): 238–46. doi:10.1016/j.ejon.2006.10.004. PMID 17350337.
- ↑ Baack BR, Burgdorf WH (1991). "Chemotherapy-induced acral erythema". J Am Acad Dermatol. 24 (3): 457–61. PMID 2061446.
- ↑ 5.0 5.1 Wysocki M, Nowaczyk-Michalak A, Pilecki O, Kurylak A, Balcar-Boroń A, Trybuś L (1992). "[Burgdorf's reaction (painful acral erythema) in patients with acute lymphoblastic leukemia following medium-dose methotrexate therapy]". Wiad Lek. 45 (11–12): 462–4. PMID 1441532.
- ↑ 6.0 6.1 Invalid
<ref>tag; no text was provided for refs namedpmid4276191 - ↑ 7.0 7.1 7.2 7.3 7.4 7.5 7.6 Farr KP, Safwat A (2011). "Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment". Case Rep Oncol. 4 (1): 229–35. doi:10.1159/000327767. PMC 3085037. PMID 21537373.
- ↑ 8.0 8.1 Krikorian A, Rahmani R, Bromet M, Bore P, Cano JP (1989). "Pharmacokinetics and metabolism of Navelbine". Semin Oncol. 16 (2 Suppl 4): 21–5. PMID 2652317.
- ↑ Harris CS, Wang D, Carulli A (2014). "Docetaxel-associated palmar-plantar erythrodysesthesia: a case report and review of the literature". J Oncol Pharm Pract. 20 (1): 73–80. doi:10.1177/1078155213475466. PMID 23478198.